BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsCIViC databaseA screening assay to identify agents that enhance T-cell recognition of human melanomasNRAS mutations are rare in colorectal cancer.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsModulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.The immune response to tumors as a tool toward immunotherapy.Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cellsNAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAGSilencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitorsBevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.Targeting Hsp90: small-molecule inhibitors and their clinical development.BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.Hsp90 as a therapeutic target in patients with oesophageal carcinoma.Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosisHsp90 inhibition: elimination of shock and stress.An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.Re-examining HSPC1 inhibitors.Increased skin papilloma formation in mice lacking glutathione transferase GSTP.A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells.Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging.Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergyViolacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
P2860
Q21284811-3FAC2427-DCE1-4F49-8608-A0E7E5853872Q27612411-11F3EFBD-A4E0-4160-9EDD-B589C3C15914Q34074758-20FA32E5-9C24-403F-A978-B95B98EA8861Q34091172-9323A0B9-A7BF-4B98-9B89-94C30CB0FD11Q34165045-CD13CB0D-9778-4B97-BEE5-DD168FB85899Q34249948-8094E944-BBCF-42A3-98C9-10545D51663AQ34634545-EC51AEE6-20D8-4E1A-8BB7-47D23244073FQ34702338-0C7647C9-9835-4F46-BFF6-3FE99EEF79D4Q35517613-B99CF74D-86CD-4749-979A-0D228CC80538Q35979667-D9C8FB0B-04D7-41BC-AA55-0D220D07CEBFQ37083059-676F0313-78E0-44DE-8F96-3E380E2DDFD3Q37154615-318E6565-2019-4A5C-B39A-414AD7AC6A56Q37222845-4C3B192C-5819-4C3E-95FC-F75CF848848CQ37399265-6DEBEFE7-60EE-44EC-AF15-3F073E9F357AQ37494634-DD94F0C9-0273-49F2-825E-B75BA220C64DQ37690758-BC92AB08-5494-4307-8DED-3D0508417070Q37697460-82E5F748-7235-4CB6-8CD8-B41E536DF472Q38291354-47E61679-3E51-4430-933C-02346F462861Q38420080-0484DFD5-7DD6-495F-8A0E-9C891CC3C4F3Q38931732-876EF8CA-A2A6-4134-A31A-63CDB8AF2D30Q39163060-CB9D0121-244F-4BCF-8850-BB43477D0571Q39472536-FE3EB654-AE21-4373-A41B-FD04781D1FFDQ41423088-96D89B51-8478-4AE5-A98A-337B87877657Q41709736-D059E67C-4835-4EE1-AC48-3623940901A8Q51584417-EDE7BDE2-F69A-4EF7-8ABD-D7ED18EE63CBQ54983509-DC82111C-3573-4FEC-95FB-EA3499786E54
P2860
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@ast
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en-gb
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@nl
type
label
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@ast
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en-gb
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@nl
prefLabel
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@ast
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en-gb
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@nl
P50
P3181
P1476
BRAF and NRAS mutations in mel ...... response to HSP90 inhibitors.
@en
P2093
Annette Affolter
Ian Judson
P3181
P356
10.1158/1535-7163.MCT-08-0145
P577
2008-04-01T00:00:00Z